Exenatide has a better hepatic–protective effect than intensive insulin therapy and perhaps represents a unique option for adjunctive therapy for patients with obesity, non-alcoholic fatty liver disease with elevated liver enzymes and T2DM. The gene discussed is INS; the disease is obesity disorder.